Literature DB >> 15927322

Immune response and alteration of pulmonary function after primary human metapneumovirus (hMPV) infection of BALB/c mice.

Magali Darniot1, Tony Petrella, Serge Aho, Pierre Pothier, Catherine Manoha.   

Abstract

Human metapneumovirus (hMPV), a recently identified virus, causes upper and lower respiratory tract diseases. In this study, we show that BALB/c mice inoculated with hMPV exhibited significant morbidity on 1--2 days post-infection, when airway obstruction was found. Increased airway hyper-responsiveness to metacholine was found on day 4 concurrent with lung viral replication. Both IgG1 and IgG2a hMPV-specific antibodies were found in sera, while interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) were found in bronchoalveolar lavage. Lung histology showed parenchymal pneumonia and increased lymphocytic infiltration. We present here an animal model that may be helpful in studying hMPV pathogenesis and evaluating the effects of vaccines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927322     DOI: 10.1016/j.vaccine.2005.04.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  19 in total

Review 1.  Modulation of Host Immunity by the Human Metapneumovirus.

Authors:  Pablo F Céspedes; Christian E Palavecino; Alexis M Kalergis; Susan M Bueno
Journal:  Clin Microbiol Rev       Date:  2016-10       Impact factor: 26.132

2.  Experimental infection of adults with recombinant wild-type human metapneumovirus.

Authors:  Kawsar R Talaat; Ruth A Karron; Bhagvanji Thumar; Bridget A McMahon; Alexander C Schmidt; Peter L Collins; Ursula J Buchholz
Journal:  J Infect Dis       Date:  2013-08-01       Impact factor: 5.226

Review 3.  Human Metapneumovirus: lessons learned over the first decade.

Authors:  Verena Schildgen; Bernadette van den Hoogen; Ron Fouchier; Ralph A Tripp; Rene Alvarez; Catherine Manoha; John Williams; Oliver Schildgen
Journal:  Clin Microbiol Rev       Date:  2011-10       Impact factor: 26.132

4.  Age-associated aggravation of clinical disease after primary metapneumovirus infection of BALB/c mice.

Authors:  M Darniot; C Pitoiset; T Petrella; S Aho; P Pothier; C Manoha
Journal:  J Virol       Date:  2009-01-14       Impact factor: 5.103

5.  T lymphocytes contribute to antiviral immunity and pathogenesis in experimental human metapneumovirus infection.

Authors:  Deepthi Kolli; Efthalia L Bataki; Leanne Spetch; Antonieta Guerrero-Plata; Alan M Jewell; Pedro A Piedra; Gregg N Milligan; Roberto P Garofalo; Antonella Casola
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

6.  Acute clearance of human metapneumovirus occurs independently of natural killer cells.

Authors:  Sherry C Wen; Sharon J Tollefson; Monika Johnson; Pavlo Gilchuk; Kelli L Boyd; Bryan Shepherd; Sebastian Joyce; John V Williams
Journal:  J Virol       Date:  2014-06-25       Impact factor: 5.103

7.  Identification of human metapneumovirus-induced gene networks in airway epithelial cells by microarray analysis.

Authors:  X Bao; M Sinha; T Liu; C Hong; B A Luxon; R P Garofalo; A Casola
Journal:  Virology       Date:  2008-01-29       Impact factor: 3.616

8.  Identification and evaluation of a highly effective fusion inhibitor for human metapneumovirus.

Authors:  Céline Deffrasnes; Marie-Eve Hamelin; Gregory A Prince; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

9.  Respiratory infections by HMPV and RSV are clinically indistinguishable but induce different host response in aged individuals.

Authors:  Vanessa Ditt; Jessica Lüsebrink; Ramona Liza Tillmann; Verena Schildgen; Oliver Schildgen
Journal:  PLoS One       Date:  2011-01-26       Impact factor: 3.240

10.  Human metapneumovirus induces more severe disease and stronger innate immune response in BALB/c mice as compared with respiratory syncytial virus.

Authors:  Barbara Huck; Dieter Neumann-Haefelin; Annette Schmitt-Graeff; Markus Weckmann; Jörg Mattes; Stephan Ehl; Valeria Falcone
Journal:  Respir Res       Date:  2007-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.